Overview
Pharmaceutical

Kidswell Bio Corporation

KidsWell Bio Corporation operates two core business segments: a Biosimilar Business, in which the company develops biosimilar pharmaceuticals and supplies active pharmaceutical ingredients (APIs) and drug products to partner pharmaceutical companies, having already launched four products since 2012; and a Cell Therapy Business (Regenerative Medicine), conducted through its wholly owned subsidiary S-Quatre Co., Ltd., which focuses on commercializing regenerative medicine products utilizing proprietary exfoliated deciduous teeth-derived stem cells (SQ-SHED). The company employs a virtual R&D model, collaborating with academia, CDMOs, and pharmaceutical partners to maximize efficiency with limited management resources. The hybrid business structure is designed to achieve both stable recurring revenues from the Biosimilar Business and high future growth potential from the Cell Therapy Business.

Market Cap
¥7.40B
US$47.2M
EV
¥6.43B
US$41.0M
Stock¥149▼-1.97%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
4.1
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-61.9%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Aug 14, 26Q1 FY2027/03 earnings announced
MC → EV Bridge
7.40BUS$47.2MMarket Cap2.48BUS$15.8M+ Debt3.23BUS$20.6M− Cash0.21BUS$1.35M− Inv. Sec.6.43BUS$41.0MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
1.57US$10.0M'22/32.78US$17.7M'23/32.43US$15.5M'24/35.08US$32.4M'25/36.59US$42.0M'26/3
EBITDA 5Y (¥B)
-0.92-US$5.85M'22/3-0.55-US$3.50M'23/3-1.33-US$8.51M'24/30.03US$0.18M'25/3-0.14-US$0.88M'26/3
Net Income 5Y (¥B)
-0.54-US$3.41M'22/3-0.66-US$4.19M'23/3-1.42-US$9.07M'24/3-0.02-US$0.13M'25/3-0.41-US$2.63M'26/3
Capital Structure
42%
58%
EquityD/E 1.37xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
1.32US$8.39M0.60US$3.83M'22/31.24US$7.91M1.45US$9.25M'23/32.37US$15.1M2.08US$13.2M'24/33.28US$20.9M1.84US$11.7M'25/33.51US$22.4M2.55US$16.3M'26/3
Shareholders
Top 10 hold 32.2%
1
Noritsu Koki Co.,Ltd.
19.08%
2
Fumishige EHIRA
4.03%
3
Nano Holdings,Inc.
2.01%
4
Rakuten Securities, Inc. (Joint Account)
1.59%
5
SENJU PHARMACEUTICAL CO.,LTD.
1.11%
6
Nomura Trust and Banking Co., Ltd. (Trust Account 2052241)
0.94%
7
Yoshihiko KITAJIMA
0.89%
8
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC; Standing Proxy: MUFG Bank, Ltd.)
0.88%
9
Kinsei TSUDA
0.88%
10
Koichi OTOMO
0.80%
Management
6 officers
Shinya BENIBAYASHI
Representative Director, President
Apr 2000 Joined Goldman Sachs Securities Co., Ltd. Aug 2009 Joined Morgan Stanley Securities Co., Ltd. (currently Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.) Oct 2014 Joined Japan Science and Technology Agency Sep 2015 Joined Regenerative Medicine Promotion Organization Co., Ltd. (currently Cell Technology Co., Ltd.); Executive Officer, General Manager of Administration Division Jun 2016 Director, General Manager of Administration Division, Regenerative Medicine Promotion Organization Co., Ltd. Aug 2016 Director, General Manager of Corporate Planning and Administration Department, Cell Technology Co., Ltd. Jan 2018 Director and Vice President, General Manager of Regenerative Medicine Business Division and Business Unit Head, Cell Technology Co., Ltd. Mar 2019 Joined the Company; Executive Officer, General Manager of Business Development Division Mar 2021 Director, Japan Regenerative Medicine Co., Ltd. Jun 2023 Representative Director, President, the Company (current) Apr 2024 Director, S-Quatre Co., Ltd. May 2026 Representative Director, President, S-Quatre Co., Ltd. (current)
1976-12-28
Norikazu SAKAEKI
Director
Apr 1969 Joined Shell Sekiyu K.K. (currently Showa Shell Sekiyu K.K.) Jun 1973 Joined Matsushita Electric Works, Ltd. (currently Panasonic Holdings Corporation) Aug 1979 Joined Nihon Ciba-Geigy K.K. (currently Novartis Pharma K.K.); General Manager, Corporate Planning Department Jan 1994 Joined Bayer Yakuhin, Ltd.; General Manager, Technical Operations Department Mar 1997 Director and Plant Manager, Shiga Plant, Bayer Yakuhin, Ltd. Jul 2002 Representative Director, President, Bayer Yakuhin, Ltd. Jan 2007 Representative Director, Chairman, Bayer Yakuhin, Ltd. Apr 2010 Director, Chairman, Bayer Yakuhin, Ltd. May 2014 Outside Director, AnGes MG, Inc. (currently AnGes, Inc.) Jun 2014 Advisor, CM Plus Co., Ltd. (current) Jan 2015 Representative Partner, Eiki Consulting LLC (current) Mar 2015 Chairman of the Board, Fanpep Inc. Jun 2015 Outside Director, Towa Pharmaceutical Co., Ltd. Apr 2016 Outside Director, Soleiah Pharma Inc. (current) Jan 2017 Outside Director, Fanpep Inc. (current) Jun 2018 Outside Director, the Company (current) Jun 2019 Outside Director (Audit and Supervisory Committee Member), Towa Pharmaceutical Co., Ltd. Aug 2023 Outside Director, AwakApp Inc. (current) Jun 2024 Outside Director, Towa Pharmaceutical Co., Ltd. (current)
1948-04-17
Sachiko NISHIOKA
Director
Jul 1986 Joined Japan Air Lines Co., Ltd. Apr 1988 Freelance announcer Jun 2000 Completed MBA program, University of Dallas (USA) Oct 2000 Joined Saison Information Systems Co., Ltd. (currently Saison Technology Co., Ltd.) Aug 2002 Joined Publicis Japan K.K.; Strategic Planner Jul 2006 Joined Gavin Anderson & Company Japan Inc. (currently Crewb); Director Sep 2011 Part-time Lecturer, Hitotsubashi University (current) Mar 2012 Established Plusna Communications Co., Ltd.; Representative Director (current) Jun 2024 Outside Director, the Company (current)
1964-01-26
Osamu SUGAWARA
Full-time Audit & Supervisory Board Member
Apr 1981 Joined Yamanouchi Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.) Oct 2001 Seconded to Yamanouchi BV (currently Astellas BV) Oct 2005 Deputy General Manager, Finance and Accounting Department, Astellas Pharma Inc. Mar 2008 Secretariat (Dedicated Staff for Audit & Supervisory Board Members), Astellas Pharma Inc. Aug 2010 Group Leader, Accounting Group, Accounting Department, Astellas Pharma Inc. Nov 2018 Joined the Company; Corporate Management Division Apr 2019 Internal Audit Office, the Company Feb 2020 Audit & Supervisory Board Member, Japan Regenerative Medicine Co., Ltd. Jun 2020 Audit & Supervisory Board Member, Cell Technology Co., Ltd. Jun 2020 Full-time Audit & Supervisory Board Member, the Company (current) Apr 2024 Audit & Supervisory Board Member, S-Quatre Co., Ltd. (current)
1958-06-07
Masato MORI
Audit & Supervisory Board Member
Oct 1987 Joined Sanwa Tohmatsu Aoki Audit Corporation (currently Deloitte Touche Tohmatsu LLC) Jul 1995 Joined Citibank, N.A. Mar 2001 Joined Plat Home Co., Ltd.; General Manager, Corporate Planning Department Jun 2001 Director, CFO and General Manager of Administration Division, Plat Home Co., Ltd. Mar 2004 Joined Nippon Telecom Co., Ltd. (currently SoftBank Corp.); General Manager, Accounting Department Jul 2005 Joined Shinsei Bank, Ltd. (currently SBI Shinsei Bank, Ltd.); General Manager, Finance and Accounting Department Aug 2006 Principal, Mori Accounting Office (current) Oct 2010 Outside Audit & Supervisory Board Member, the Company (current) May 2016 Outside Audit & Supervisory Board Member, Sobal Corporation
1965-03-20
Hiroshi SHINAGAWA
Audit & Supervisory Board Member
Oct 2002 Joined Hamada & Matsumoto (currently Mori Hamada & Matsumoto) Sep 2009 Seconded to Investment Banking Division, Morgan Stanley Securities Co., Ltd. (currently Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.) Jan 2012 Opened Nishiki-dori Law Office (currently Nishiki-dori Law Office, Kanda Branch, M Partners Attorneys at Law); Attorney-at-law (current) Mar 2013 Supervisory Officer, Hoshino Resorts REIT Inc. (current) Jun 2015 Outside Audit & Supervisory Board Member, Mirai Works Inc. (current) Mar 2016 Outside Audit & Supervisory Board Member, Cell Technology Co., Ltd. Jul 2017 Outside Audit & Supervisory Board Member, Infucurion Group Inc. (currently Infucurion Inc.) (current) Sep 2018 Outside Audit & Supervisory Board Member, Metsera Inc. Mar 2020 Outside Director (Audit and Supervisory Committee Member), Japan System Co., Ltd. May 2020 Outside Audit & Supervisory Board Member, Aderans Co., Ltd. (current) Jun 2020 Outside Audit & Supervisory Board Member, the Company (current) Sep 2022 Outside Director (Audit and Supervisory Committee Member), Metsera Inc. Apr 2024 Outside Audit & Supervisory Board Member, Metsera Inc. (current)
1976-12-07
Large Shareholding Reports
Heights Capital Management, Inc.
2026-07-29
5.14%→4.55%
Noritsu Koki Co., Ltd.
2026-05-21
32.60%→19.08%
Annual report (as of 2026-03-31): 19.08%
Heights Capital Management, Inc.
2025-09-26
6.14%→5.14%
Heights Capital Management, Inc.
2025-08-27
7.42%→6.14%
Heights Capital Management, Inc.
2025-08-21
8.93%→7.42%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-13
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-07-29
Large Shareholding Report
EDINET
2026-06-29
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-05-21
Large Shareholding Report
TDnet
2026-02-12
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-09-26
Large Shareholding Report
EDINET
2025-08-27
Large Shareholding Report
EDINET
2025-08-21
Large Shareholding Report
TDnet
2025-08-13
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-27
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-12
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-12-26
Securities Registration Statement
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-14
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-27
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINETAmended
2024-06-07
Amended Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-14
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINETAmended
2023-08-25
Amended Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-07-10
Securities Registration Statement
EDINET
2023-06-30
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-12
Quarterly Securities Report
EDINET
2022-06-28
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-10
Quarterly Securities Report
EDINET
2021-08-13
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →